Compare DCBO & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | IVVD |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 489.9M | 437.1M |
| IPO Year | 2020 | 2021 |
| Metric | DCBO | IVVD |
|---|---|---|
| Price | $19.71 | $1.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $32.00 | $8.75 |
| AVG Volume (30 Days) | 215.2K | ★ 1.9M |
| Earning Date | 05-08-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | $12.54 | $143.48 |
| Revenue Next Year | $11.82 | $25.40 |
| P/E Ratio | $22.04 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $16.07 | $0.46 |
| 52 Week High | $33.69 | $3.07 |
| Indicator | DCBO | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 53.28 | 34.31 |
| Support Level | $18.11 | $1.41 |
| Resistance Level | $20.15 | $2.00 |
| Average True Range (ATR) | 0.97 | 0.13 |
| MACD | 0.18 | -0.02 |
| Stochastic Oscillator | 46.83 | 1.83 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.